Reader TTS

ABSTRACT Treatment for non-metastatic breast cancer (BC) may be the cause of second malignancies in long-term survivors. Our aim was to investigate whether survivors present a higher risk of

malignancy than the general population according to treatment received. We analysed data for 16 705 BC survivors treated at the Curie Institute (1981–1997) by either chemotherapy (various

regimens), radiotherapy (high-energy photons from a 60Co unit or linear accelerator) and/or hormone therapy (2–5 years of tamoxifen). We calculated age-standardized incidence ratios (SIRs)

for each malignancy, using data for the general French population from five regional registries. At a median follow-up 10.5 years, 709 patients had developed a second malignancy. The

greatest increases in risk were for leukaemia (SIR: 2.07 (1.52–2.75)), ovarian cancer (SIR: 1.6 (1.27–2.04)) and gynaecological (cervical/endometrial) cancer (SIR: 1.6 (1.34–1.89);

_P_<0.0001). The SIR for gastrointestinal cancer, the most common malignancy, was 0.82 (0.70–0.95; _P_<0.007). The increase in leukaemia was most strongly related to chemotherapy and

that in gynaecological cancers to hormone therapy. Radiotherapy alone also had a significant, although lesser, effect on leukaemia and gynaecological cancer incidence. The increased risk of

sarcomas and lung cancer was attributed to radiotherapy. No increased risk was observed for malignant melanoma, lymphoma, genitourinary, thyroid or head and neck cancer. There is a

significantly increased risk of several kinds of second malignancy in women treated for BC, compared with the general population. This increase may be related to adjuvant treatment in some

cases. However, the absolute risk is small. SIMILAR CONTENT BEING VIEWED BY OTHERS MORTALITY AFTER SECOND MALIGNANCY IN BREAST CANCER SURVIVORS COMPARED TO A FIRST PRIMARY CANCER: A

NATIONWIDE LONGITUDINAL COHORT STUDY Article Open access 14 July 2022 ASSOCIATION BETWEEN RADIATION THERAPY FOR PRIMARY ENDOMETRIAL CANCER AND RISK OF SECOND PRIMARY MALIGNANCIES: A

RETROSPECTIVE COHORT STUDY Article Open access 19 October 2024 LOCOREGIONAL TUMOR BURDEN AND RISK OF MORTALITY IN METASTATIC BREAST CANCER Article Open access 05 April 2022 MAIN The overall

survival rate of patients with early advanced breast cancer (BC) has increased over the years largely because adjuvant therapy, whether chemotherapy, radiotherapy or hormone therapy, has

helped prevent local and distant failures (Fox, 1979; Jones and Raghavan, 1993; EBCTCG, 2005). Second malignancies that occur in long-term survivors may be due to sporadic cancers that would

have occurred anyway, environmental or genetic factors (Klijn et al, 1997; Schrag et al, 1997; Turner et al, 1999; Meijers-Heijboer et al, 2000; Pierce et al, 2000, 2003; Stoppa-Lyonnet et

al, 2000; Galper et al, 2002; Kauff et al, 2002; Pierce, 2002; Robson, 2002; Seynaeve et al, 2004; Kirova et al, 2005a, 2005b, 2006a; Laki et al, 2007), or BC treatment (Neugut et al, 1993;

Inskip et al, 1994; Ahsan and Neugut, 1998; Karlsson et al, 1998; Kirova et al, 1998, 2005a, 2005b, 2007; Obedian et al, 2000; Rubino et al, 2000; Scholl et al, 2001; Shousha et al 2001; Yap

et al, 2002, 2005; Deutsch et al, 2003; Zablotska and Neugut, 2003; Zablotska et al, 2005; Mellemkjaer et al, 2006) The aim of this study was to estimate the risk of a second malignancy

after adjuvant treatment for BC in a homogeneous cohort of patients from a single institution. The observed incidence of second malignancies in these BC patients was compared with the

expected age-adjusted number of new cases in the general population of French women as given by data from five regional registries (Remontet et al, 2003). PATIENTS AND METHODS We analysed

data for 16 705 consecutive patients with non-metastatic BC who were treated at the Institut Curie between 1981 and 1997. The data, including treatments, were entered prospectively into the

Institute's BC database set up in 1981 (Salmon et al, 1997). Chemotherapy regimens in adjuvant and neoadjuvant setting varied over time based on CMF (cyclophosphamide, methotrexate and

5-fluorouracile), FAC (5-fluorouracile, adriamycine and cyclophosphamide) or FEC (epirubicin). All patients received alkylating agents and the majority received anthracyclins. Hormonal

therapy consisted mostly of 2–5 years of administration of tamoxifen. Patients who underwent radiotherapy received high-energy photons produced by a 60Co unit or linear accelerator, as

previously described, either as sole treatment or pre- or post surgery (Fourquet et al, 1991; Campana et al, 2005; Kirova et al, 2006b). Follow-up included a six-monthly clinical examination

and a once-yearly mammogram for 5 years, and then a once-yearly clinical examination and a unilateral or bilateral mammogram for the lifetime of every patient. All follow-up data were

entered into the database. At 5 years, 5% of patients were lost to follow-up and at 10 years, 8% were lost to follow-up. We recorded clinical and primary tumour variables, radiation history

and irradiation fields, for all patients with histologically confirmed second malignancies. Second malignancies included all first cancers occurring after treatment of the primary BC, but

excluded contralateral BC. STATISTICAL ANALYSIS We first calculated Kaplan–Meier cumulative incidence and the 10-year risk of developing each type of second malignancy (Kaplan and Meier,

1958). The observed crude incidence rates in the entire patient population (cases per 100 000 person-years) were then compared with the expected incidence in the general population of French

women as given by age-standardized data from five regional registries (Remontet et al, 2003), and a standardized incidence ratio (SIR) was calculated for each malignancy. We then calculated

the SIRs for the highest-risk malignancies according to the adjuvant treatment the patients had received to study the impact of treatment on risk. The Poisson regression model was used to

adjust the analysis. The data were analysed using ‘S Plus 6.2, Insightful Corp.’ software. RESULTS Median follow-up was 10.5 years (range 0.2–24 years). Median patient age at the time of BC

diagnosis was 56.2 years. Of the total population of 16 705 patients, 13 472 (80.6%) received radiation therapy, 2347 (17.4%) underwent mastectomy followed by radiotherapy, 8596 (63.8%)

lumpectomy then radiotherapy, and 2529 (18.8%) were treated by radiotherapy alone. A total of 4528 patients (27.1%) received chemotherapy (14.3% chemotherapy alone; 12.8% chemotherapy plus

hormone therapy) and 16.5% received hormone therapy alone. Overall, 9414 patients (56.4%) did not receive any systemic adjuvant therapy. The number of patients receiving different treatment

combinations is given in Table 1. By 10.5 years of median follow-up, 709 patients had developed a second malignancy. Table 2 gives the cumulative incidence of second malignancies 10.5 years

after BC in the study population by decreasing order of incidence. Gastrointestinal (GI) cancer was the most common cancer, followed by gynaecological cancer (cervical and endometrial) and

ovarian cancer. Table 3 compares the observed crude incidence in patients and the incidence in the general population of French women. Of all the malignancies, only leukaemia, ovarian and

other gynaecological cancers (cervical and endometrial), and GI tumours, showed a significantly higher incidence in patients than in the general population. Among the 74 patients with

histologically confirmed primary ovarian cancer, 13 underwent genetic testing because they presented a familial history of BC or ovarian cancer and, of these 13 patients, 10 were carriers of

_BRCA_ mutations (9 of _BRCA1_, 1 of _BRCA2_). The extent to which the different treatments constituted risk factors for a second malignancy is shown in Table 4. Chemotherapy was the most

important risk factor for leukaemia and highly significantly increased the risk of this disease. Radiotherapy was a much less significant risk factor. Both hormone treatment and radiotherapy

were significant risk factors for gynaecological cancers. The SIR of ovarian cancer was threefold higher in patients who had received radiotherapy plus chemotherapy than in patients

receiving no adjuvant therapy. The combination treatment was a highly significant risk factor. Chemotherapy alone had no significant effect maybe because of the small number of events and

lack of statistical power. We found no relationship between GI tumours and BC treatment (not shown). DISCUSSION To our knowledge, this is the largest retrospective study from a single

institution on second malignancies and one of the first to attempt to relate the incidence and risk of a second malignancy in patients with non-metastatic BC to the expected number of cases

in the general population of women of the same age, after stratifying patients by treatment received (Rubino et al, 2000). Patients treated for BC showed increased risk of leukaemia, ovarian

cancer, and gynaecological cancers, and a slightly enhanced risk of GI cancers, in addition to the well-known risk of developing sarcomas (Kirova et al, 2005b) and lung cancer after

radiation therapy (Kirova et al, 2007). The increase in leukaemia was most strongly related to chemotherapy (alkylating agents) and that in gynaecological cancers to hormone therapy (the

main treatment was tamoxifen). Radiation therapy alone also had a significant, but lesser, effect found only in comparison with the general population (Rubino et al, 2000). There was no

difference between irradiated and non-irradiated patients with regard to leukaemia risk (Kirova et al, 2007), but there was a significant difference between our patients and the general

population. Such a difference has already been noted and has been related to the use of adjuvant chemotherapy (7, 13, 19, 34; Rubino et al, 2000). At the Institut Gustave Roussy, the overall

SIR for leukaemia was 3.1 (95% confidence interval (CI): 1.7–5.0) in 4416 BC patients and 2.1 (95% CI: 1.1–3.5) in the subpopulation of 416 patients receiving chemotherapy (Rubino et al,

2000). Our observation of an increased risk of ovarian cancer confirms previous findings (Easton et al, 1993; Breast Cancer Linkage Consortium, 1997; Fisher et al, 1998; Chappuis et al,

2000; Haber, 2002; Haffty et al, 2002; Kauff et al, 2002; Pierce et al, 2003; Blamey et al, 2004) and suggests that these patients may have a familial predisposition to BC and ovarian

cancer. Although we tested 13 of 74 patients with ovarian cancer for _BRCA1_ or _BRCA2_ mutations and found a mutation in 10 of the 13 patients with familial cancer, this result is not

representative of the whole population of patients. We included patients as from 1981, but only began genetic testing in the early nineties. The increased risk of endometrial cancer might be

due to tamoxifen use, as shown by others (Ewertz and Mouridsen, 1985; Brenner et al, 1993; Volk and Pompe-Kirn, 1997). Confirmation of this would need distinguishing different types of

hormone therapy (anti-estrogens, anti-aromatase) from surgical hysterectomy and radiation-induced castration. No relationship between GI cancers and different treatment modalities was

observed. This and our previous study did not find increased incidence of oesophageal cancers, related to the radiation treatment (Kirova et al, 2007). A major strength of our study is the

large volume of individual patient data from a single institution. This differentiates it from epidemiological studies that lack individual data on patient treatment and from most

single-institution series that are much smaller. However, despite the large number of patients and long follow-up (10.5 years), the incidence of second malignancies may nevertheless remain

underestimated because of the long latency period of some tumours. In conclusion, this study has confirmed an increased risk of second malignancies in women treated for BC, compared with the

general population. This increase may be related to adjuvant treatment in some cases. However, the absolute risk is small and the influence of other predisposing factors, such as for

instance family history of cancer and history of smoking, will need to be investigated in a prospective study, preferably with a long enough follow-up to exclude other late complications.

CHANGE HISTORY * _ 16 NOVEMBER 2011 This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication _ REFERENCES * Ahsan H,

Neugut AI (1998) Radiation therapy for breast cancer and increased risk for esophageal carcinoma. _Ann Int Med_ 128: 114–117 Article  CAS  Google Scholar  * Blamey RW, Mackay J, Macmillan D

(2004) EUSOMA guidelines on the management of familial breast cancer risk. _Eur J Cancer_ 2: 155 (abstract) Article  Google Scholar  * Breast Cancer Linkage Consortium (1997) Pathology of

familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. _Lancet_ 349: 1505–1510 Article  Google Scholar  * Brenner H, Siegle S,

Stegmaier C, Ziegler H (1993) Second primary neoplasms following breast cancer in Saarland, Germany, 1968–1987. _Eur J Cancer_ 29: 1410–1414 Article  Google Scholar  * Campana F, Kirova YM,

Rosenwald JC, Dendale R, Vilcoq JR, Dreyfus H, Fourquet A (2005) Breast radiotherapy in the lateral decubitus position – a technique to prevent lung and heart irradiation. _Int J Radiat

Oncol Biol Phys_ 61: 1348–1354 Article  Google Scholar  * Chappuis PO, Nethercot V, Foulkes WD (2000) Clinico-pathological characteristics of BRCA1 and BRCA2-related breast cancer. _Semin

Surg Oncol_ 8: 287–295 Article  Google Scholar  * Deutsch M, Land SR, Begovic M, Wieand HS, Wolmark N, Fisher B (2003) The incidence of lung carcinoma after surgery for breast carcinoma with

and without postoperative radiotherapy. Results of NSABP clinical trials B-04 and B-06. _Cancer_ 98: 1362–1368 Article  Google Scholar  * Early Breast Cancer Trialists’ Collaborative Group

(EBCTCG) (2005) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomized trials.

_Lancet_ 366: 2087–2106 Article  Google Scholar  * Easton DF, Bishop DT, Ford D, Crockford GP (1993) Genetic linkage analysis in familial breast and ovarian cancer: results from 214

families. The Breast Cancer Linkage Consortium. _Am J Hum Genet_ 52: 678–701 CAS  PubMed  PubMed Central  Google Scholar  * Ewertz M, Mouridsen H (1985) Second cancer following cancer of the

female breast in Denmark, 1943–80. _Natl Cancer Inst Monogr_ 68: 325–329 CAS  PubMed  Google Scholar  * Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V,

Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel

Project P-1 study. _J Natl Cancer Inst_ 90: 1371–1388 Article  CAS  Google Scholar  * Fourquet A, Campana F, Rosenwald JC, Vilcoq JR (1991) Breast irradiation in the lateral decubitus

position: technique of the Institut Curie. _Radiother Oncol_ 22: 261–265 Article  CAS  Google Scholar  * Fox MS (1979) On the diagnosis and treatment of breast cancer. _JAMA_ 241: 489–494

Article  CAS  Google Scholar  * Galper S, Gelman R, Recht A, Silver B, Kohli A, Wong JS, Van Buren T, Baldini EH, Harris JR (2002) Second non breast malignancies after conservative surgery

and radiation therapy for early stage breast cancer. _Int J Radiat Oncol Biol Phys_ 52: 406–414 Article  Google Scholar  * Haber D (2002) Prophylactic oophorectomy to reduce the risk of

ovarian and breast cancer in carriers of BRCA mutations. _N Engl J Med_ 346: 1660–1662 Article  Google Scholar  * Haffty BG, Harrold E, Khan AJ, Pathare P, Smith TE, Turner BC, Glazer PM,

Ward B, Carter D, Matloff E, Bale AE, Alvarez-Franco M (2002) Outcome of conservatively managed early-onset breast cancer by BRCA1/BRCA2 status. _Lancet_ 359: 1471–1477 Article  Google

Scholar  * Inskip PD, Stoval M, Flannery JT (1994) Lung cancer risk and radiation dose among women treated for breast cancer. _J Natl Cancer Inst_ 86: 983–988 Article  CAS  Google Scholar  *

Jones VE, Raghavan D (1993) Quantum leaps in treatment of high-risk breast cancer? Prove it!. _Eur J Cancer_ 10: 1488–1493 Article  Google Scholar  * Kaplan EL, Meier P (1958)

Non-parametric estimation from incomplete observations. _J Am Stat Assoc_ 53: 457–481 Article  Google Scholar  * Karlsson P, Holmberg E, Samuelsson A, Johansson KA, Wallgren A (1998) Soft

tissue sarcoma after treatment for breast cancer – a Swedish population-based study. _Eur J Cancer_ 34: 2068–2075 Article  CAS  Google Scholar  * Kauff ND, Satagopan JM, Robson ME, Scheuer

L, Hensley M, Hudis CA, Ellis NA, Boyd J, Borgen PI, Barakat RR, Norton L, Castiel M, Nafa K, Offit K (2002) Risk reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. _N

Engl J Med_ 346: 1609–1615 Article  Google Scholar  * Kirova Y, Savignoni A, Stoppa-Lyonnet D, Sigal-Zafrani B, Fourquet A (2006a) Risk of second non breast cancer in relation to _BRCA1 and

BRCA2_ mutation status following breast-conserving treatment. _Eur J Cancer_ 4: 127–128 (abst 276) Article  Google Scholar  * Kirova Y, Servois V, Campana F, Dendale R, Bollet MA, Laki F,

Fourquet A (2006b) CT-scan based localization of the internal mammary chain and supra clavicular nodes for breast cancer radiation therapy planning. _Radiother Oncol_ 79: 310–315 Article 

Google Scholar  * Kirova YM, Feuilhade F, Calitchi E, Otmezguine Y, Le Bourgeois JP (1998) Radiation-induced sarcomas following radiotherapy for breast cancer: six case reports and a review

of the literature. _Breast_ 7: 277–282 Article  Google Scholar  * Kirova YM, Gambotti L, De Rycke Y, Vilcoq JR, Asselain B, Fourquet A (2007) Risk of second malignancies (SM) following

adjuvant radiotherapy (RT) for breast cancer (BC): a large scale single institution review. _Int J Radiat Oncol Biol Phys_ 68: 359–363 Article  Google Scholar  * Kirova YM, Stoppa-Lyonnet D,

Savignoni A, Sigal-Zafrani B, Fabre N, Fourquet A, for the Institut Curie Breast Cancer Study Group (2005a) Risk of second non breast malignancies (SNBM) in relation to _BRCA1_ and _BRCA2_

mutation status following breast-conserving surgery and radiotherapy. _Eur J Cancer_ 41: 2304–2311 Article  Google Scholar  * Kirova YM, Vilcoq JR, Asselain B, Sastre-Garau X, Fourquet A

(2005b) Radiation-induced sarcomas (RIS) following radiotherapy for breast cancer: a large-scale single institution review. _Cancer_ 104: 856–863 Article  Google Scholar  * Klijn JG, Janin

N, Cortés-Funes H, Colomer R (1997) Should prophylactic surgery be used in women at high risk of breast cancer? _Eur J Cancer_ 33: 2149–2159 Article  CAS  Google Scholar  * Laki F, Kirova

YM, This P, Plancher C, Asselain B, Sastre X, Stoppa-Lyonnet D, Salmon R (2007) Prophylactic salpingo-oophorectomy in a series of 89 women carrying a _BRCA1_ or _a BRCA2_ mutation. _Cancer_

109: 1784–1790 Article  CAS  Google Scholar  * Meijers-Heijboer EJ, Verhoog LC, Brekelmans CT, Seynaeve C, Tilanus-Linthorst MM, Wagner A, Dukel L, Devilee P, van den Ouweland AM, van Geel

AN, Klijn JG (2000) Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation. _Lancet_ 355: 2015–2020 Article  CAS  Google Scholar  * Mellemkjaer L,

Friis S, Olsen JH, Scélo G, Hemminki K, Tracey E, Andersen A, Brewster DH, Pukkala E, McBride ML, Kliewer EV, Tonita JM, Kee-Seng C, Pompe-Kirn V, Martos C, Jonasson JG, Boffetta P, Brennan

P (2006) Risk of second cancer among women with breast cancer. _Int J Cancer_ 118: 2285–2292 Article  CAS  Google Scholar  * Neugut AI, Robinson E, Lee WC, Murray T, Karwoski K, Kutcher GJ

(1993) Lung cancer after radiation therapy for breast cancer. _Cancer_ 71: 3054–3057 Article  CAS  Google Scholar  * Obedian E, Fischer DB, Haffty BG (2000) Second malignancies after

treatment of early stage breast cancer. Lumpectomy and radiation therapy _vs_ mastectomy. _J Clin Oncol_ 18: 2406–2412 Article  CAS  Google Scholar  * Pierce L, Levin A, Rebbeck T (2003)

Ten-year outcome of breast-conserving surgery and radiotherapy in women with breast cancer and germline BRCA1/2 mutations: results from an international collaboration. _Breast Cancer Res

Treat_ 82: S7 (#5), (abstr) Article  Google Scholar  * Pierce L (2002) Radiotherapy for breast cancer in BRCA1/BRCA2 carriers: clinical issues and management dilemmas. _Semin Radiat Oncol_

12: 352–361 Article  Google Scholar  * Pierce LJ, Strawderman M, Narod SA, Oliviotto I, Eisen A, Dawson L, Gaffney D, Solin LJ, Nixon A, Garber J, Berg C, Isaacs C, Heimann R, Olopade OI,

Haffty B, Weber BL (2000) Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. _J Clin Oncol_ 18: 3360–3369 Article  CAS 

Google Scholar  * Remontet L, Buemi A, Velten M, Jougla E, Estève J (2003) Evolution de l’incidence et de la mortalité par cancer en France de 1978 à 2000 * Robson ME (2002) Clinical

considerations in the management of individuals at risk for hereditary breast and ovarian cancer. _Cancer Control_ 9: 457–465 Article  Google Scholar  * Rubino C, de Vathaire F, Diallo I,

Shamsaldin A, G Lê M (2000) Increased risk of second cancers following breast cancer: role of the initial treatment. _Breast Cancer Res Treat_ 61: 183–195 Article  CAS  Google Scholar  *

Salmon RJ, Asselain B, Le Gal M (1997) Twelve years experience of breast cancer at the Institut Curie: improvement of survival and value of screening mammographics. _Breast_ 6: 202–205

Article  Google Scholar  * Scholl B, Reis ED, Zouhair A, Chereshnev I, Givel JC, Gillet M (2001) Esophageal cancer as second primary tumor after breast cancer radiotherapy. _Am J Surg_ 182:

476–480 Article  CAS  Google Scholar  * Schrag D, Kuntz KM, Garber JE, Weeks JC (1997) Decision analysis – effects of prophylactic mastectomy and oophorectomy on life expectancy among women

with BRCA1 or BRCA2 mutations. _N Engl J Med_ 336: 1465–1471 Article  CAS  Google Scholar  * Seynaeve C, Verhoog LC, van de Bosch LM, van Geel AN, Menke-Pluymers M, Meijers-Heijboer EJ, van

den Ouweland AM, Wagner A, Creutzberg CL, Niermeijer MF, Klijn JG, Brekelmans CT (2004) Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy.

_Eur J Cancer_ 40: 1150–1158 Article  CAS  Google Scholar  * Shousha S, Fawcett A, Luqmani YA, Theodorou N (2001) Multifocal squamous cell carcinoma of the oesophagus following radiotherapy

for bilateral breast carcinoma. _J Clin Pathol_ 54: 718–720 Article  CAS  Google Scholar  * Stoppa-Lyonnet D, Ansquer Y, Dreyfus H, Gautier C, Gauthier-Villars M, Bourstyn E, Clough KB,

Magdelénat H, Pouillart P, Vincent-Salomon A, Fourquet A, Asselain B (2000) Familial invasive breast cancers: worse outcome related to BRCA1 mutations. _J Clin Oncol_ 18: 4053–4059 Article 

CAS  Google Scholar  * Turner BC, Harrold E, Matloff E, Smith T, Gumbs AA, Beinfield M, Ward B, Skolnick M, Glazer PM, Thomas A, Haffty BG (1999) BRCA1/BRCA2 germline mutations in locally

recurrent breast cancer patients after lumpectomy and radiation therapy: implications for breast-conserving management in patients with BRCA1/BRCA2 mutations. _J Clin Oncol_ 17: 3017–3024

Article  CAS  Google Scholar  * Volk N, Pompe-Kirn V (1997) Second primary cancers in breast cancer patients in Slovenia. _Cancer Causes Control_ 8: 764–770 Article  CAS  Google Scholar  *

Yap J, Chuba PJ, Thomas R, Aref A, Lucas D, Severson RK, Hamre M (2002) Sarcoma as a second malignancy after treatment for breast cancer. _Int J Radiat Oncol Biol Phys_ 52: 1231–1237 Article

  Google Scholar  * Zablotska LB, Chak A, Das A, Neugut AI (2005) Increased risk of squamous cell esophageal cancer after adjuvant radiation therapy for primary breast cancer. _Am J

Epidemiol_ 161: 330–337 Article  Google Scholar  * Zablotska LB, Neugut AI (2003) Lung carcinoma after radiation therapy in women treated with lumpectomy or mastectomy for primary breast

carcinoma. _Cancer_ 97: 1404–1411 Article  Google Scholar  Download references ACKNOWLEDGEMENTS We acknowledge Chantal Gautier and Muriel Belotti for help in data management. This study did

not receive any grant support. AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Department of Radiation Oncology, Institut Curie, Paris, France Y M Kirova & A Fourquet * Department of

Biostatistics, Institut Curie, Paris, France Y De Rycke, L Gambotti & B Asselain * Department of Medical Oncology, Institut Curie, Paris, France J-Y Pierga Authors * Y M Kirova View

author publications You can also search for this author inPubMed Google Scholar * Y De Rycke View author publications You can also search for this author inPubMed Google Scholar * L Gambotti

View author publications You can also search for this author inPubMed Google Scholar * J-Y Pierga View author publications You can also search for this author inPubMed Google Scholar * B

Asselain View author publications You can also search for this author inPubMed Google Scholar * A Fourquet View author publications You can also search for this author inPubMed Google

Scholar CONSORTIA FOR THE INSTITUT CURIE BREAST CANCER STUDY GROUP CORRESPONDING AUTHOR Correspondence to Y M Kirova. ADDITIONAL INFORMATION Presented in part at the 29th San Antonio Breast

Cancer Symposium, December 2006. CONFLICT OF INTEREST None. RIGHTS AND PERMISSIONS From twelve months after its original publication, this work is licensed under the Creative Commons

Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ Reprints and permissions ABOUT THIS

ARTICLE CITE THIS ARTICLE Kirova, Y., De Rycke, Y., Gambotti, L. _et al._ Second malignancies after breast cancer: the impact of different treatment modalities. _Br J Cancer_ 98, 870–874

(2008). https://doi.org/10.1038/sj.bjc.6604241 Download citation * Received: 19 November 2007 * Revised: 29 December 2007 * Accepted: 07 January 2008 * Published: 12 February 2008 * Issue

Date: 11 March 2008 * DOI: https://doi.org/10.1038/sj.bjc.6604241 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a

shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative KEYWORDS * breast cancer * second

malignancies * second malignant neoplasms * radiotherapy * chemotherapy * hormone therapy * long-term risk